| __timestamp | Agios Pharmaceuticals, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 1802274 |
| Thursday, January 1, 2015 | 35992000 | 2512761 |
| Friday, January 1, 2016 | 50714000 | 2894488 |
| Sunday, January 1, 2017 | 71124000 | 8096274 |
| Monday, January 1, 2018 | 114145000 | 7985229 |
| Tuesday, January 1, 2019 | 132034000 | 8994597 |
| Wednesday, January 1, 2020 | 149070000 | 29772000 |
| Friday, January 1, 2021 | 121445000 | 33907000 |
| Saturday, January 1, 2022 | 121673000 | 26579000 |
| Sunday, January 1, 2023 | 119903000 | 49868547 |
| Monday, January 1, 2024 | 156784000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Agios Pharmaceuticals, Inc. and Verona Pharma plc have taken different paths in optimizing these costs. From 2014 to 2023, Agios Pharmaceuticals saw a steady increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. Meanwhile, Verona Pharma maintained a more conservative approach, with a notable spike in 2023, reaching 27 times their 2014 expenses. This divergence highlights Agios's aggressive growth strategy, while Verona's recent surge suggests a strategic pivot. As the industry evolves, these trends offer insights into how companies balance growth with cost management, a critical factor for investors and stakeholders alike.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Catalent, Inc. and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.